WHAT IS CLAIMED IS:

1. A method of loading antigen in a dendritic cell for antigen presentation, the method comprising:

modifying a pluripotent stem cell with a nucleic acid molecule encoding an antigen or one or more immunogenic epitopes thereof;

inducing the pluripotent stem cell to differentiate into a dendritic cell that expresses and presents the antigen or the one or more immunogenic epitopes thereof.

2. The method of claim 1, wherein the pluripotent stem cell is an induced pluripotent stem cell.

3. The method of claim 1 or 2, wherein the pluripotent stem cell is stably modified with the nucleic acid molecule.

4. The method of any one of claims 1 to 3, wherein modifying comprises transducing using a viral or nonviral method to deliver the nucleic acid molecule into the pluripotent stem cell.

5. The method of claim 4, wherein the viral or nonviral method is able to provide long-term transgene expression.

6. The method of any one of claims 1 to 5, wherein the modifying comprises transducing the pluripotent stem cell with a retroviral vector, preferably a lentiviral vector.

7. The method of any one of claims 1 to 6, wherein the pluripotent stem cell is a mammalian cell, preferably a human cell.

8. The method of any one of claims 1 to 7, wherein the antigen is a full-length antigen.

9. The method of any one of claims 1 to 8, wherein the antigen is a tumor antigen, a viral antigen, a bacterial antigen or an autoimmune disease antigen.

10. The method of claim 9, wherein the antigen is a tumour antigen.

11. The method of any one of claims 1 to 10, wherein the nucleic acid molecule further encodes a targeting sequence fused to the antigen or the one or more immunogenic epitopes

thereof, preferably a proteosomal targeting sequence, for example a ubiquitin sequence, or an endosomal targeting sequence.

12. A dendritic cell that is derived from a pluripotent stem cell, the pluripotent stem cell stably modified with a nucleic acid molecule encoding an antigen or one or more immunogenic epitopes thereof, wherein the dendritic cell expresses and presents the antigen or the one or more immunogenic epitopes thereof.

13. The dendritic cell of claim 12, wherein the cell expresses one or more of CD11c, CD86 and HLA.

14. A vaccine comprising the dendritic cell of claim 12 or 13, optionally comprising an adjuvant and/or a pharmaceutically acceptable excipient or diluent.

15. Use of the dendritic cell of claim 12 or 13 or the vaccine of claim 14 for inducing an immune response in a subject, preferably a T-cell mediated response.

16. Use of the dendritic cell of claim 12 or 13 in the manufacture of a vaccine for inducing an immune response in a subject, preferably a T-cell mediated response.

17. The use of claim 15 or 16, wherein the dendritic cell is autologous with the subject.

18. The use of claim 15 or 16, wherein the dendritic cell is allogeneic with the subject.

19. The use of claim 18, wherein the dendritic cell is at least partially MHC-matched with the subject.

20. The use of any one of claims 15 to 19, glioma, prostate cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, or gastrointestinal cancer, and the antigen is a tumour antigen.